Roche And Genentech In Marketing Deal
Roche's US arm, Hoffmann-La Roche Inc, and Genentech of the USA haveentered into an agreement under the terms of which Genentech will promote Roche's Roferon-A (interferon alfa-2a) in the USA for its approved oncology indications.
Roche will continue to market Roferon-A for its newest indication, the treatment of chronic hepatitis C, as part of an existing copromotion agreement with Gilead Sciences (Marketletters passim).
Genentech's president and chief executive, Arthur Levinson, said: "this agreement supports Genentech's efforts to build a strong oncology franchise. Our product pipeline includes several cancer therapies in clinical research, two of which are in late-stage development. By marketing Roferon-A, we will have the opportunity to enhance our knowledge of the oncology market as we move our oncology pipeline products through development."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze